Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06812052 · ClinicalTrials.gov registry record · Phase 1
Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery
A Phase 1 study of Retroperitoneal Sarcoma, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06812052 is a Phase 1 study of Retroperitoneal Sarcoma that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 6 participants, below the 415-participant average among 6 other Retroperitoneal Sarcoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06812052, a Phase 1 study of Retroperitoneal Sarcoma, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the safety of moderately hypofractionated radiation in the treatment of primary and locally recurrent RPS, based on the evaluation of acute radiation-related toxicity profile of each participant (30-day radiation toxicity)
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- RADIATION Hypofractionationed Radiation Therapy
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital / Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2025-05-29 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06812052
The ClinicalTrials.gov registry entry for NCT06812052 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 415-participant average among 6 other Retroperitoneal Sarcoma trials with a reported enrollment target (99% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retroperitoneal Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT06812052 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06812052 about?
NCT06812052 is a clinical study titled "Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery". To determine the safety of moderately hypofractionated radiation in the treatment of primary and locally recurrent RPS, based on the evaluation of acute radiation-related toxicity profile of each participant (30-day radiation toxicity)
What is the current status of trial NCT06812052?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2025-05-29. Estimated completion is 2026-11.
What conditions does trial NCT06812052 study?
This clinical trial studies the following conditions: Retroperitoneal Sarcoma.
What interventions are being tested in trial NCT06812052?
The interventions under investigation include: Radiation Therapy (RADIATION), Hypofractionationed Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT06812052?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06812052 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retroperitoneal Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma
RECRUITING · Phase 1
-
Proton or Photon RT for Retroperitoneal Sarcomas
RECRUITING · Phase 1
-
Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
RECRUITING · Phase 3
-
REtroperitoneal SArcoma Registry: an International Prospective Initiative
RECRUITING
-
Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.